UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/621,941	07/17/2003	Peter Gingras	14188-002001	1557
<sup>26161</sup> FISH & RICH <i>A</i>	7590 09/21/200 ARDSON PC	EXAMINER		
P.O. BOX 1022		SWEET, THOMAS		
MINNEAPOLIS, MN 55440-1022			ART UNIT	PAPER NUMBER
			3774	
			NOTIFICATION DATE	DELIVERY MODE
			09/21/2009	ELECTRONIC

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

	Application No.	Applicant(s)
	10/621,941	GINGRAS, PETER
Office Action Summary	Examiner	Art Unit
	Thomas J. Sweet	3774
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING ID.  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory or Failure to reply within the set or extended period for reply will, by stature Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION  .136(a). In no event, however, may a reply be tind  d will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. mely filed I the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 14 / 2a) This action is <b>FINAL</b> . 2b) This 3) Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4)  Claim(s) 1-12,15-23,25 and 85 is/are pending 4a) Of the above claim(s) 4-7 is/are withdrawr 5)  Claim(s) is/are allowed. 6)  Claim(s) 1-3, 8-12,15-23,25 and 85 is/are rejection claim(s) is/are objected to. 8)  Claim(s) are subject to restriction and/	n from consideration.	
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the edrawing(s) be held in abeyance. Se ction is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of:  1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority documer application from the International Burea * See the attached detailed Office action for a lis	nts have been received. nts have been received in Applicat ority documents have been receive au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:	ate

### **DETAILED ACTION**

#### Election/Restrictions

The restriction requirement of 6/22/09 has been withdrawn.

### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 04/14/2009 has been entered.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-3, 8-10, 12, 15-23, 25 and 85 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pacetti et al (US 6355058) in view of Mano et al (US Re. 31618). Pacetti et al discloses a non-woven soft tissue implant (stent, fig 1) comprising a porous biocompatible film (16, fig. 2) having a plurality of cells (as shown in fig. 1), a thickness of less than about 0.015 inches (col 4, lines 24-27), and a surface area ratio less than 1.5 (inherent, as clearly seen in fig. 1, plus its expandable to much smaller ratio), wherein the biocompatible film (16) comprises one or more films (film-a thin layer or coating) of polymer or copolymer. However, Pacetti et al

Art Unit: 3774

remains silent (states "codrawn" but doesn't specifically mention extruding) as to the polymer or copolymer having biaxially oriented chains. Mano et al teaches another non-woven soft tissue implant which is extruded and stretched to form a biaxially oriented tube (col 3, line 1-25) for the purpose of strengthening the tube. It would have been obvious to one of ordinary skill in the art at the time the invention was made to utilize an extruded and stretched biaxially oriented tube as taught by Mano et al as the stent material of Pacetti et al in order to strengthen the material.

Regarding claims 9 and 10, The non-woven soft tissue implant of claim 1, wherein one or more of the cells in the plurality of cells has a diameter, measured along the longest axis of the cell, of about 10 microns to about 10,000 microns. ("There is no inherent limitation on the stent's diameter or length, and as such will be dependent upon a particular application for the stent.", col 7, lines 39-41, given a typical stent diameter of ½ and inch or less meets this claim based on the drawings. Note- precise proportions are not being used in this rejection).

Regarding claim 12, fully expanded the cells are rectangular so the cells are essentially rectangular at any expansion.

Regarding claim 15, 25 micron equates to about 0.001 inches.

Claims 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pacetti et al (US 6355058) in view of Mano et al (US Re. 31618) as applied to claim 9 above and in further view of Wulfman et al (US 20030139802). Pacetti et al as modified disclosed a non-woven soft tissue implant as discussed above. However, Pacetti et al does not disclose one or more of the cells in the plurality of cells has a diameter, measured along the longest axis of the cell, of about 50 microns to about 100 microns. Wulfman et al teaches another a non-woven soft tissue implant including cells less than about 100 microns (14, claim 8, encompassing 50 microns to 100

Art Unit: 3774

microns) for the purpose of reinforcing the structure as a critical point. It would have been obvious to one of ordinary skill in the art at the time the invention was made to utilize a cell size of less than 100 microns (including 50-100) as taught by Wulfman et al on the stent material of Pacetti et al in order to reinforcing the structure as a critical point.

# Allowable Subject Matter

The indicated allowability of claim 11 is withdrawn in view of the newly discovered reference(s) to Wulfman et al. The current and previous changes to the independent claim changes the limitations on claim 11 required a new search.

#### Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See the enclosed 892 form.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas J. Sweet whose telephone number is 571-272-4761. The examiner can normally be reached on 6:45am - 5:15pm, Tu-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David J. Isabella can be reached on 571-272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/621,941 Page 5

Art Unit: 3774

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Thomas J Sweet/ Primary Examiner, Art Unit 3774